IP Library Granted Patent US 12,297,230
Granted Patent B2
US 12,297,230 · App. 18/316,102 · Granted May 13, 2025

Synthetic system for tunable thresholding of protein signals

Inventors: Lucy S. Chong (Pasadena, CA); Ronghui Zhu (Pasadena, CA); Xiaofei Ge (Beijing, CN); Michael B. Elowitz (Pasadena, CA); Mark W. Budde (Arcadia, CA)
Assignee: California Institute of Technology
C07K14/001C12N9/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,297,230
App. No.
18/316,102
Granted
May 13, 2025
Kind
B2
Abstract

Disclosed herein include methods, compositions, and kits suitable for use in thresholding of protein signals. There are provided, in some embodiments, synthetic protein circuits that respond to inputs only above or below a certain threshold concentration. In some embodiments, the threshold value itself is tunable. Methods of treating a disease or disorder characterized by aberrant signaling are provided in some embodiments.

Claims (38)

1. A method of thresholding protein signals comprising:

expressing a synthetic protein circuit in a cell, the synthetic protein circuit comprising:

a first input polypeptide comprising a first partner domain and a first polypeptide domain;

a second input polypeptide comprising a second partner domain and a second polypeptide domain, wherein the first partner domain is capable of binding the second partner domain, wherein the first polypeptide domain and the second polypeptide domain are capable of associating with each other to constitute a first protein capable of being in a first protein active state when the first partner domain binds the second partner domain; and

a thresholding polypeptide comprising a third partner domain and a third polypeptide domain, wherein the third partner domain is capable of binding the second partner domain, wherein the first protein is not in the first protein active state when the third partner domain binds the second partner domain, wherein the first protein in the first protein active state is capable of generating a thresholding output.

2. The method of claim 1 , wherein the expressing comprises administering a nucleic acid encoding the synthetic protein circuit, or

wherein the expressing comprises administering two or more nucleic acids, and wherein the two or more nucleic acids encode the synthetic protein circuit.

3. The method of claim 2 , wherein the nucleic acid comprises at least one regulatory element for expression of the synthetic protein circuit.

4. The method of claim 2 , wherein the nucleic acid comprises a vector,

optionally: wherein the vector comprises an adenovirus vector, an adeno-associated virus vector, an Epstein-Barr virus vector, a Herpes virus vector, an attenuated HIV vector, a retroviral vector, a vaccinia virus vector, or any combination thereof,

wherein the vector comprises an RNA viral vector,

wherein the vector is derived from one or more negative-strand RNA viruses of the order Mononegavirales, and/or

the vector is a rabies viral vector.

5. The method of claim 1 , wherein

(i) the third polypeptide domain and the second polypeptide domain are incapable of associating to form the first protein in the first protein active state,

(ii) the third polypeptide domain and the second polypeptide domain are capable of associating with each other to constitute a first protein capable of being in a first protein inactive state when the third partner domain binds the second partner domain, or

(iii) the third polypeptide domain and the second polypeptide domain are capable of associating with each other to constitute a first protein capable of being in a first protein dominant negative state when the third partner domain binds the second partner domain.

6. The method of claim 1 , wherein the thresholding output comprises a first enzymatic reaction with a substrate generating a first product.

7. The method of claim 6 , wherein the substrate comprises a nucleic acid, a protein, a lipid, or any combination thereof.

8. The method of claim 1 , wherein the third partner domain and the second partner domain are capable of inducing trans-splicing of the thresholding polypeptide and second input polypeptide when the second partner domain binds the third partner domain, thereby generating a conjugate comprising the second polypeptide domain and the third polypeptide domain, optionally wherein the conjugate is not capable of being in the first protein active state.

9. The method of claim 1 , wherein the first partner domain has a reduced binding affinity for the second partner domain as compared to the binding affinity of the third partner domain for the second partner domain, or

wherein the first partner domain binds the second partner domain with a first binding affinity, wherein the third partner domain binds the second partner domain with a second binding affinity, wherein the first partner domain is a variant of the third partner domain that is configured to reduce the first binding affinity, wherein the first partner domain comprises one or more mutations as compared to the third partner domain, and wherein the one or more mutations reduce the first binding affinity by at least 10 percent as compared to the second binding affinity.

10. The method of claim 1 , wherein a thresholding output level is related to a number of molecules of the first protein in the first protein active state.

11. The method of claim 6 , wherein a thresholding output level is related to a number of molecules of the first product.

12. The method of claim 1 , wherein the thresholding output is generated in response to a first input.

13. The method of claim 12 , wherein a first output is generated in response to the first input, wherein a first output level positively correlates with a first input level and wherein the thresholding output is generated in response to the first output.

14. The method of claim 13 , wherein the first output comprises a first protease in a first protease active state and wherein the first output level is related to a number of molecules of the first protease in a first protease active state.

15. The method of claim 1 , wherein the thresholding output level generated below a threshold first input level is less than about 5% as compared to the thresholding output level generated at or above the threshold first input level.

16. The method of claim 1 , wherein no thresholding output is generated below a threshold second input polypeptide concentration, or

wherein the thresholding output level generated below a threshold second input polypeptide concentration is less than about 5% as compared to the thresholding output level generated at or above the threshold second input polypeptide concentration.

17. The method of claim 1 , wherein the synthetic protein circuit is capable of inducing cell death in the presence of the aberrant signaling of a first signal transducer, or when a first level of activation of the first signal transducer is above a first signal transducer activation threshold.

18. A synthetic protein circuit, comprising:

a first input polypeptide comprising a first partner domain and a first polypeptide domain;

a second input polypeptide comprising a second partner domain and a second polypeptide domain, wherein the first partner domain is capable of binding the second partner domain, wherein the first polypeptide domain and the second polypeptide domain are capable of associating with each other to constitute a first protein capable of being in a first protein active state when the first partner domain binds the second partner domain; and

a thresholding polypeptide comprising a third partner domain and a third polypeptide domain, wherein the third partner domain is capable of binding the second partner domain, wherein the first protein is not in the first protein active state when the third partner domain binds the second partner domain, wherein the first protein in the first protein active state is capable of generating a thresholding output,

wherein the third partner domain and the second partner domain are capable of inducing trans-splicing of the thresholding polypeptide and second input polypeptide when the second partner domain binds the third partner domain, thereby generating a conjugate comprising the second polypeptide domain and the third polypeptide domain, optionally wherein the conjugate is not capable of being in the first protein active state.

19. The synthetic protein circuit of claim 18 , wherein the first partner domain, second partner domain, and/or third partner domain comprise an intein-N, an intein-C, a fragment thereof, or any combination thereof.

20. The synthetic protein circuit of claim 18 , wherein (1) the first partner domain comprises the amino acid sequence of SEQ ID NO: 9; (2) the second partner domain comprises the amino acid sequence of SEQ ID NO: 8; and/or (3) the third partner domain comprises the amino acid sequence of any one of SEQ ID NOs: 7, 10, and 11.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2023
From: ELOWITZ, MICHAEL B.
To: HOWARD HUGHES MEDICAL INSTITUTE
Reel/Frame 063631/0679 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2023
From: HOWARD HUGHES MEDICAL INSTITUTE
To: CALIFORNIA INSTITUTE OF TECHNOLOGY
Reel/Frame 063631/0694 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2023
From: CHONG, LUCY S.; ZHU, RONGHUI; GE, XIAOFEI; BUDDE, MARK W.
To: CALIFORNIA INSTITUTE OF TECHNOLOGY
Reel/Frame 063631/0702 →
Continuity (3)
Continuation 16738664 · Jan 9, 2020
Provisional Application 62790553 · Jan 10, 2019
Related Publication 20240101606A1 · Mar 28, 2024
References Cited (155)
US 5739002A · De Francesco et al. · 1998 [cited by applicant]
US 6005079A · Casterman et al. · 1999 [cited by applicant]
US 6348584B1 · Hodgson et al. · 2002 [cited by applicant]
US 6673901B2 · Koide · 2004 [cited by applicant]
US 6856914B1 · Pelech · 2005 [cited by applicant]
US 6884870B2 · Hav et al. · 2005 [cited by applicant]
US 8394604B2 · Liu et al. · 2013 [cited by applicant]
US 10899823B2 · Gao et al. · 2021 [cited by applicant]
US 11453893B2 · Gao et al. · 2022 [cited by applicant]
US 11542305B2 · Gao et al. · 2023 [cited by applicant]
US 11667676B2 · Chong · 2023 [cited by examiner]
US 20020132327A1 · Hay et al. · 2002 [cited by applicant]
US 20050271647A1 · Baltimore et al. · 2005 [cited by applicant]
US 20080227750A1 · Dennis et al. · 2008 [cited by applicant]
US 20090162341A1 · Foster et al. · 2009 [cited by applicant]
US 20130230863A1 · Tang et al. · 2013 [cited by applicant]
US 20150315570A1 · Zhao et al. · 2015 [cited by applicant]
US 20160223529A1 · Stein et al. · 2016 [cited by applicant]
US 20170315114A1 · Stein et al. · 2017 [cited by applicant]
US 20180118818A1 · Tang et al. · 2018 [cited by applicant]
US 20190248873A1 · Gao et al. · 2019 [cited by applicant]
US 20210238570A1 · Gao et al. · 2021 [cited by applicant]
WO WO1994004678 · 1994 [cited by applicant]
WO WO1994025591 · 1994 [cited by applicant]
WO WO2014040129 · 2014 [cited by applicant]
WO WO2015017214 · 2015 [cited by applicant]
WO WO2015164594 · 2015 [cited by applicant]
WO WO2018069782 · 2018 [cited by applicant]
WO WO2019147478 · 2019 [cited by applicant]
Adams et al., “Overview and analysis of the polyprotein cleavage sites in the family Potyviridae,” Molecular Plant Pathology 2005, 6(4), 471-487. [cited by applicant]
Angelici et al., “Synthetic Biology Platform for Sensing and Integrating Endogenous Transcriptional Inputs in Mammalian Cells,” Cell Reports 2016, 16, 2525-2537. [cited by applicant]
Aronheim et al., “Membrane Targeting of the Nucleotide Exchange Factor Sos Is Sufficient for Activating the Ras Signaling Pathway,” Cell 1994, 78 ,949-961. [cited by applicant]
Auslander et al., “Programmable single-cell mammalian biocomputers,” Nature 2012, 487, 123-127. [cited by applicant]
Banaszynski et al., “A Rapid, Reversible, and Tunable Method to Regulate Protein Function in Living Cells Using Synthetic Small Molecules,” Cell 2006, 126, 995-1004. [cited by applicant]
Barnea et al., “The genetic design of signaling cascades to record receptor activation,” PNAS 2008, 105(1), 64-69. [cited by applicant]
Barrett et al., “Chimeric Antigen Receptor Therapy for Cancer,” Annual Review of Medicine 2014, 65, 333-347. [cited by applicant]
Bartenschlager et al., “The NS3/4A proteinase of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy,” Journal of Viral Hepatitis 1999, 6, 165-181. [cited by applicant]
Basu et al., “A synthetic multicellular system for programmed pattern formation,” Nature 2005, 434, 1130-1134. [cited by applicant]
Basu et al., “Spatiotemporal control of gene expression with pulse-generating networks,” PNAS 2004, 101(17), 6355-6360. [cited by applicant]
Bintu et al., “Dynamics of epigenetic regulation at the single-cell level,” Science 2016, 351(6274), 720-724. [cited by applicant]
Boerger et al., “Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types,” PNAS 1999, 96, 9867-9872. [cited by applicant]
Bonnet et al., “Amplifying Genetic Logic Gates,” Science 2013, 340, 599-602. [cited by applicant]
Budihardjo et al., “Biochemical Pathways of Caspase Activation During Apoptosis,” Annual Review of Cellular Development and Biology 1999, 15, 269-290. [cited by applicant]
Butko et al., “Fluorescent and photo-oxidizing TimeSTAMP tags track protein fates in light and electron microscopy,” Nature Neuroscience 2012, 15(12), 1742-1751. [cited by applicant]
Camacho-Soto et al., “Ligand-Gated Split-Kinases,” Journal of the American Chemical Society 2014, 136, 3995-4002. [cited by applicant]
Camacho-Soto et al., “Small Molecule Gated Split-Tyrosine Phosphatases and Orthogonal Split-Tyrosine Kinases,” Journal of the American Chemical Society 2014, 136, 17078-17086. [cited by applicant]
Carrington et al., “A viral cleavage site cassette: Identification of amino acid sequences required for tobacco etch virus polyprotein processing,” PNAS 1988, 85, 3391-3395. [cited by applicant]
Chen et al., “Predicting PDZ domain-peptide interactions from primary sequences,” Nature Biotechnology 2008, 26(9), 1041-1045. [cited by applicant]
Choi et al., “Selective viral vector transduction of ErbB4 expressing cortical interneurons in vivo with a viral receptor-ligand bridge protein,” PNAS 2010, 107(38), 16703-16708. [cited by applicant]
Chung et al., “Tunable and reversible drug control of protein production via a self-excising degron,” Nature Chemical Biology 2015, 11, 713-720. [cited by applicant]
Corrected Notice of Allowance dated Aug. 31, 2022 in U.S. Appl. No. 16/556,063. [cited by applicant]
Corrected Notice of Allowance dated Jun. 29, 2022 in U.S. Appl. No. 16/555,604. [cited by applicant]
Cox et al., “Drugging the undruggable Ras: mission possible?,” Nature Reviews Drug Discovery 2014, 13(11), 828-851. [cited by applicant]
Dagliyan et al., “Computational design of chemogenetic and optogenetic split proteins,” Nature Communications, 9(4042), 1-8, (2018). [cited by applicant]
Daringer et al., “Modular Extracellular Sensor Architecture for Engineering Mammalian Cell-based Devices,” ACS Synthetic Biology 2014, 3, 892-902. [cited by applicant]
De Felipe et al., “Targeting of Proteins Derived from Self-Processing Polyproteins Containing Multiple Signal Sequences,” Traffic 2004, 5, 616-626. [cited by applicant]
De Felipe, “Skipping the co-expression problem: the new 2A “Chysel” technology,” Genetic Vaccines and Therapy 2004, 2(13). [cited by applicant]
Dissing et al., “Autoproteolysis and feedback in a protease cascade directing [cited by applicant]
Downward, “Targeting RAS Signaling Pathways in Cancer Therapy,” Nature Publishing Group 2003, 3, 11-22. [cited by applicant]
Dueber et al., “Reprogramming Control of an Allosteric Signaling Switch Through Modular Recombination,” Science 2003, 301, 1904-1908. [cited by applicant]
Elowitz et al., “A synthetic oscillatory network of transcriptional regulators,” Nature 2000, 403, 335- 338. [cited by applicant]
Extended European Search Report dated Jun. 15, 2022 in European Patent Application No. 19854896.8. [cited by applicant]
Fernandez-Rodriguez et al., “Post-translational control of genetic circuits using Potyvirus proteases,” Nucleic Acids Research 2016, 44(13), 6493-6502. [cited by applicant]
Ferrell et al., “Ultrasensitivity Part II: Multisite phosphorylation, stoichiometric inhibitors, and positive feedback,” Trends in Biochemical Sciences 2014, 39(11), 556-569. [cited by applicant]
Fink et al., “Design of fast proteolysis-based signaling and logic circuits in mammalian cells,” Nature Chemical Biology 2018, 15, 115-122. [cited by applicant]
Gao et al., “Programmable protein circuits in living cells,” Science 2018, 361, 1252-1258. [cited by applicant]
Gardner et al., “Construction of a genetic toggle switch in Escherichia coli,” Nature, 403, 339-342. [cited by applicant]
Ghabrial et al., “Molecular genetic analyses of the soybean mosaic virus Nla proteinase,” Journal of General Virology 1990, 71, 1921-1927. [cited by applicant]
Ghosh et al., “Antiparallel Leucine Zipper-Directed Protein Reassembly: Application to the Green Fluorescent Protein,” Journal of the American Chemical Society 2000, 122, 5658-5659. [cited by applicant]
Gramespacher et al., “Intein Zymogens: Conditional Assembly and Splicing of Split Inteins via Targeted Proteolysis,” Journal of the American Chemical Society 2017, 139, 8074-8077. [cited by applicant]
Gray et al., “Activation of Specific Apoptotic Caspases with an Engineered Small Molecule-Activated Protease,” Cell 2010, 142(4), 637-646. [cited by applicant]
Greber et al., “An engineered mammalian band-pass network,” Nucleic Acids Research 2010, 38(18), e174. [cited by applicant]
Griesbeck et al., “Reducing the Environmental Sensitivity of Yellow Fluorescent Protein,” The Journal of Biological Chemistry 2001, 276(31), 29188-29194. doi:10.1074/jbc.M102815200. [cited by applicant]
Hancock et al., “A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of ras proteins,” The EMBO Journal 1991, 10(13), 4033-4039. [cited by applicant]
Hart et al., “The Utility of Paradoxical Components in Biological Circuits,” Molecular Cell 2013, 49, 213-221. [cited by applicant]
Herrmann et al., “Quantitative Analysis of the Complex between p21ras and the Ras-binding Domain of the Human Raf-1 Protein Kinase,” Journal of Biological Chemistry 1995, 270(7), 2901-2905. [cited by applicant]
Holt, Brandon Alexander, and Gabriel A. Kwong. “Protease circuits for processing biological information.” [cited by applicant]
Howard et al., “Redirecting tyrosine kinase signaling to an apoptotic caspase pathway through chimeric adaptor proteins,” PNAS 2003, 100(20), 11267-11272. [cited by applicant]
International Search Report and Written Opinion dated Aug. 12, 2019 in PCT Patent Application PCT/US2019/014078. [cited by applicant]
International Search Report and Written Opinion dated Dec. 19, 2019 in PCT Patent Application PCT/US2019/048914. [cited by applicant]
International Search Report and Written Opinion dated May 7, 2020 in PCT Patent Application PCT/US2020/012928. [cited by applicant]
Iwamoto et al., “A General Chemical Method to Regulate Protein Stability in the Mammalian Central Nervous System,” Chemistry & Biology 2010, 17, 981-988. [cited by applicant]
Jacobs et al., “StaPLs: versatile genetically encoded modules for engineering drug-inducible proteins,” Nature Methods 2018, 15(7), 523-526. [cited by applicant]
Khalil et al., “A Synthetic Biology Framework for Programming Eukaryotic Transcription Functions,” Cell 2012, 150, 647-658. [cited by applicant]
Kim et al., “Time-gated detection of protein-protein interactions with transcriptional readout,” eLife 2017, 6, e30233. [cited by applicant]
Kipniss et al., “Engineering cell sensing and responses using a GPCR-coupled CRISPR-Cas system,” Nature Communications 2017, 8, 2212. [cited by applicant]
Koch-Nolte et al., “Single domain antibodies from llama effectively and specifically block T cell ecto-ADP-ribosyltransferase ART2.2 in vivo,” The FASEB Journal 2007, 21, 3490-3498. [cited by applicant]
Koh et al., “An Internal Ribosome Entry Site (IRES) Mutant Library for Tuning Expression Level of Multiple Genes in Mammalian Cells,” PLOS One 2013, 8(12), e82100. [cited by applicant]
Kojima et al., “Toward a world of theranostic medication: Programming biological sentinel systems for therapeutic intervention,” Advanced Drug Delivery Reviews 2016, 105, 66-76. [cited by applicant]
Lichty et al., “Vesicular stomatitis virus: re-inventing the bullet,” Trends in Molecular Medicine 2004, 10(5), 210-216. [cited by applicant]
Lienert et al., “Synthetic biology in mammalian cells: Next generation research tools and therapeutics,” Nature Reviews of Molecular Cell Biology 2014, 15(2), 95-107. [cited by applicant]
Lohmueller et al., “A tunable zinc finger-based framework for Boolean logic computation in mammalian cells,” Nucleic Acids Research 2012, 40(11), 5180-5187. [cited by applicant]
Lonzaric et al., “Design and applications of synthetic information processing circuits in mammalian cells,” Synthetic Biology 2018, 2, 1-34. [cited by applicant]
Ma et al., “Defining Network Topologies that Can Achieve Biochemical Adaptation,” Cell 2009, 138, 760-773. [cited by applicant]
Marchisio et al., “Computational design of synthetic gene circuits with composable parts,” Bioninformatics 2008, 24(17), 1903-1910. [cited by applicant]
Morsut et al., “Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors,” Cell 2016, 164(4), 780-791. [cited by applicant]
Nakanishi et al., Development of Sendai Virus Vectors and their Potential Applications in Gene Therapy and Regenerative Medicine, Current Gene Therapy 2012, 12, 410-416. [cited by applicant]
Nallamsetty et al., “Efficient site-specific processing of fusion proteins by tobacco vein mottling virus protease in vivo and in vitro,” Protein Expression and Purification 2004, 38, 108-115. [cited by applicant]
Nelson, “Antibody fragments,” mAbs 2010, 2(1), 77-83. [cited by applicant]
Nielsen et al., “Genetic circuit design automation,” Science 2016, 352(6281), aac7341. [cited by applicant]
Nissim et al., “A tunable dual-promoter integrator for targeting of cancer cells,” Molecular Systems Biology 2010, 6(444), 1-9. [cited by applicant]
Non-final Office Action dated Apr. 18, 2022 in U.S. Appl. No. 16/556,063. [cited by applicant]
Non-final Office Action dated Jun. 14, 2022 in U.S. Appl. No. 16/738,664. [cited by applicant]
Non-final Office Action dated Jun. 28, 2023 in U.S. Appl. No. 17/157,880. [cited by applicant]
Notice of Allowance dated Aug. 24, 2022 in U.S. Appl. No. 16/556,063. [cited by applicant]
Notice of Allowance dated Dec. 20, 2023 in U.S. Appl. No. 17/157,880. [cited by applicant]
Notice of Allowance dated Jan. 26, 2023 in U.S. Appl. No. 16/738,664. [cited by applicant]
Notice of Allowance dated May 18, 2022 in U.S. Appl. No. 16/555,604. [cited by applicant]
Notice of Allowance Dated Nov. 22, 2023 in U.S. Appl. No. 17/935,024. [cited by applicant]
Notice of Allowance Dated Sep. 16, 2020 in U.S. Appl. No. 16/250,314. [cited by applicant]
Oliveira et al., “An Improved Ras Sensor for Highly Sensitive and Quantitative FRET-FLIM Imaging,” PLOS One 2013, 8(1), e52874. [cited by applicant]
Park et al., “Rewiring MAP Kinase Pathways Using Alternative Scaffold Assembly Mechanisms,” Science 2003, 299, 1061-1064. [cited by applicant]
Partial European Search Report dated Nov. 19, 2021 in European Patent Application 19743690.0. [cited by applicant]
Porcher et al., “The Bicoid Morphogen System,” Current Biology 2010, 20(5), R249-R254. [cited by applicant]
Pu et al., “Evolution of a split RNA polymerase as a versatile biosensor platform,” Nature Chemical Biology 2017, 13(4), 432-438. [cited by applicant]
Reinke et al., “A synthetic coiled-coil interactome provides heterospecific modules for molecular engineering,” Journal of the American Chemical Society 2010, 132(17), 6025-6031. [cited by applicant]
Restriction Requirement Dated Dec. 7, 2021 in U.S. Appl. No. 16/738,664. [cited by applicant]
Restriction Requirement Dated Dec. 9, 2019 in U.S. Appl. No. 16/250,314. [cited by applicant]
Restriction Requirement Dated Feb. 24, 2023 in U.S. Appl. No. 17/157,880. [cited by applicant]
Restriction Requirement Dated Sep. 28, 2021 in U.S. Appl. No. 16/556,063. [cited by applicant]
Riechmann et al., “Single domain antibodies: comparison of camel VH and camelised human VH domains,” Journal of Immunological Methods 1999, 231, 25-38. [cited by applicant]
Rinaudo et al., “A universal RNAi-based logic evaluator that operates in mammalian cells,” Nature Biotechnology 2007, 1-6. [cited by applicant]
Roquet et al., “Synthetic recombinase-based state machines in living cells,” Science 2016, 353(6297), aad8559. [cited by applicant]
Rossi et al., “Monitoring protein-protein interactions in intact eukaryotic cells by b-galactosidase complementation,” PNAS 1997, 94, 8405-8410. [cited by applicant]
Roybal et al., “Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits,” Cell 2016, 164, 770-779. [cited by applicant]
Russell et al., “Oncolytic Virotherapy,” Nature Biotechnology 2012, 30(7). [cited by applicant]
Schnell et al., “Infectious rabies viruses from cloned cDNA,” The EMBO Journal 1994, 13(18), 4195-4203. [cited by applicant]
Schwanhausser et al. “Global quantification of mammalian gene expression control” Nature 2011, 473, 337-342. [cited by applicant]
Shekhawat et al., “An Autoinhibited Coiled-Coil Design Strategy for Split-Protein Protease Sensors,” J. Am. Chem Soc. 2009, 131, 15284-15290. [cited by applicant]
Snitkovsky et al., “A TVA-Single-Chain Antibody Fusion Protein Mediates Specific Targeting of a Subgroup A Avian Leukosis Virus Vector to Cells Expressing a Tumor-Specific Form of Epidermal Growth Factor Receptor,” Jour… [cited by applicant]
Stein et al., “Protease-based synthetic sensing and signal amplification,” PNAS 2014, 1-6. [cited by applicant]
Stein et al., “Synthetic protein switches: design principles and applications,” Trends in Biotechnology 2015, 33(2), 101-110. [cited by applicant]
Stein et al., “Ultrasensitive Scaffold-Dependent Protease Sensors with Large Dynamic Range,” ACS Synthetic Biology 2017, 6, 1337-1342. [cited by applicant]
Stevens et al., “Design of a Split Intein with Exceptional Protein Splicing Activity,” Journal of the American Chemical Society 2016, 138, 2162-2165. [cited by applicant]
Stricker et al. “A fast, robust and tunable synthetic gene oscillator,” Nature 2008, 456, 516-520. [cited by applicant]
Supplementary Partial European Search Report dated Nov. 19, 2021 in European Application No. 19743690.0. [cited by applicant]
Szymczak et al., “Correction of multi-gene deficiency in vivo using a single ‘self-cleaving’ 2A peptide-based retroviral vector,” Nature Biotechnology 2004, 22, 589-594. [cited by applicant]
Tang et al., “Detection and manipulation of live antigen-expressing cells using conditionally stable nanobodies,” eLIFE 2016, 5, 1-27. [cited by applicant]
Taremi et al., “Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease,” Protein Science 1998, 7, 2143-2149. [cited by applicant]
Taxis et al., “Efficient protein depletion by genetically controlled deprotection of a dormant N-degron,” Molecular Systems Biology 2009, 5(267), 1-7. [cited by applicant]
To et al., “Rationally designed fluorogenic protease reporter visualizes spatiotemporal dynamics of apoptosis in vivo,” PNAS 2015, 112(11), 3338-3343. [cited by applicant]
Tozser et al., “Comparison of the substrate specificity of two potyvirus proteases,” The FEBS Journal 2005, 272, 514-523. [cited by applicant]
Truong et al., “Development of an intein-mediated split-Cas9 system for gene therapy,” Nucleic Acids Research 2015, 43(13), 6450-6458. [cited by applicant]
Varshavsky, “The N-end rule: Functions, mysteries, uses,” PNAS 1996, 93, 12142-12149. [cited by applicant]
Waugh, “An overview of enzymatic reagents for the removal of affinity tags,” Protein Expression and Purification 2011. [cited by applicant]
Wehr et al., “Monitoring regulated protein-protein interactions using split TEV,” Nature Methods 2006, 3(12), 985-993. [cited by applicant]
Weinberg et al., “Large-scale design of robust genetic circuits with multiple inputs and outputs for mammalian cells,” Nature Biotechnology 2017, 35(5), 453-462. [cited by applicant]
Weinheimer et al., “Autoproteolysis of Herpes Simplex Virus Type 1 Protease Releases an Active Catalytic Domain Found in Intermediate Capsid Particles,” Journal of Virology 1993, 67(10), 5813-5822. [cited by applicant]
Wikstrand et al., “The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target,” Journal of NeuroVirology 1998, 4, 148-158. [cited by applicant]
Wroblewska et al., “Mammalian synthetic circuits with RNA binding proteins delivered by RNA,” Nature Biotechnology 2015, 33(8), 839-841. [cited by applicant]
Wu, Yiqian, and Yingxiao Wang. “Protein circuits reprogram cells.” Nature chemical biology 15.2 (2019): 96-97. [cited by applicant]
Xie et al., “Multi-Input RNAi-Based Logic Circuit for Identification of Specific Cancer Cells,” Science 2011, 333, 1307-1311. [cited by applicant]
Yasuda et al., “Supersensitive Ras activation in dendrites and spines revealed by two-photon fluorescence lifetime imaging,” Nature Neuroscience 2006, 9(2), 283-291. [cited by applicant]
Yeh et al., “Rewiring cellular morphology pathways with synthetic guanine nucleotide exchange factors,” Nature 2007, 447, 596-600. [cited by applicant]
Zetche et al., “A Split Cas9 Architecture for Inducible Genome Editing and Transcription Modulation,” Nature Biotechnology 2015, 33(2), 139-142. [cited by applicant]